Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.62 -0.85 (-1.43%)
Official Closing Price Updated: 7:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,060,100
Open 59.79
Bid (Size) 58.60 (200)
Ask (Size) 58.75 (200)
Prev. Close 59.47
Today's Range 58.46 - 59.80
52wk Range 42.52 - 62.89
Shares Outstanding 2,222,113,553
Dividend Yield 4.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap ↗
Healthcare never sleeps. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
Via Finterra
Topics Earnings Economy Intellectual Property

Performance

YTD
+9.7%
+9.7%
1 Month
-0.6%
-0.6%
3 Month
+5.1%
+5.1%
6 Month
+34.6%
+34.6%
1 Year
+15.6%
+15.6%

More News

Read More
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
Via MarketMinute
Topics Artificial Intelligence
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Via MarketMinute
News headline image
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Value Stocks Walking a Fine Line
Via StockStory
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
Via MarketMinute
News headline image
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
Via StockStory
News headline image
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
From Bristol Myers Squibb
Via Business Wire
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
Via MarketMinute
Topics Intellectual Property
News headline image
Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb
Via StockStory
News headline image
Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
Via StockStory
Topics Artificial Intelligence
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
Via MarketMinute
News headline image
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
From Bristol Myers Squibb
Via Business Wire
News headline image
1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
From Bristol Myers Squibb
Via Business Wire

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 58.62
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 04/10/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 130.26B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 130B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>